Trading the Move, Not the Narrative: (ACAD) Edition
This article analyzes Acadia Pharmaceuticals Inc. (NASDAQ: ACAD) providing trading strategies based on AI models. It highlights weak near and mid-term sentiment but a neutral long-term outlook, identifying an exceptional risk-reward setup targeting a 14.2% gain. The piece outlines specific position trading, momentum breakout, and risk hedging strategies for ACAD.
Assessing ACADIA Pharmaceuticals (ACAD) Valuation After Pipeline Progress And Product Rollouts
ACADIA Pharmaceuticals (ACAD) is being evaluated after recent pipeline progress, including developments in remlifanserin and the rollout of DAYBUE's STIX formulation. Despite a year-to-date share price decline of over 20%, Simply Wall St's analysis suggests the stock is undervalued with a fair value of $28.75 against its current trading price of $20.95. This valuation hinges on successful clinical execution and product uptake, with potential risks from trial setbacks or weaker-than-expected sales.
ACADIA Pharmaceuticals Spotlights Alzheimer’s Psychosis Pipeline, NUPLAZID and DAYBUE Growth
ACADIA Pharmaceuticals discussed its clinical pipeline, particularly remlifanserin for Alzheimer's disease psychosis, during an RBC Capital Markets investor session. The company also provided updates on the commercial performance of NUPLAZID and DAYBUE, including sales force expansion and a new DAYBUE STIX formulation. ACADIA aims to advance its pipeline and business development by focusing on both late-stage and early-stage neuroscience and rare disease assets.
ACADIA Pharmaceuticals Spotlights Alzheimer’s Psychosis Pipeline, NUPLAZID and DAYBUE Growth
ACADIA Pharmaceuticals discussed its clinical pipeline, focusing on remlifanserin for Alzheimer’s disease psychosis, emphasizing higher exposure and improved trial design. The company also provided updates on the commercial performance of NUPLAZID and DAYBUE, noting the early impact of a sales force expansion for NUPLAZID and the positive reception of the new DAYBUE STIX formulation. Additionally, ACADIA is proceeding with a European reexamination for DAYBUE and exploring new business development opportunities in neuroscience and rare diseases.
How ACADIA’s (ACAD) Solid Q1 Revenue and Pipeline Update Has Changed Its Investment Story
ACADIA Pharmaceuticals Inc. reported solid first-quarter 2026 results with increased revenue and reaffirmed its full-year 2026 revenue guidance, including sales ranges for NUPLAZID and DAYBUE. The company highlighted its focus on expanding these commercial products and anticipates upcoming Phase 2 data for remlifanserin, which is expected to be a key near-term catalyst and significantly influence the stock's future. This update helps reshape ACADIA’s investment narrative, with projected revenue of $1.6 billion and earnings of $286.9 million by 2029, suggesting a potential 49% upside to its current price according to some analyses.
How ACADIA’s (ACAD) Solid Q1 Revenue and Pipeline Update Has Changed Its Investment Story
ACADIA Pharmaceuticals Inc. reported Q1 2026 revenue of US$268.06 million, with net income falling to US$3.64 million, while reaffirming full-year revenue guidance of US$1.22 billion to US$1.28 billion. The company is focusing on expanding sales for NUPLAZID and DAYBUE and anticipates upcoming phase 2 data for remlifanserin, which is a key near-term catalyst. This update could significantly reshape ACADIA's investment narrative, with analysts projecting varied future revenues and fair values.
ACADIA Pharmaceuticals stock (US0042251084): Biotech decline amid CNS focus
ACADIA Pharmaceuticals (ACAD) has seen a 19.2% stock decline year-to-date in 2026, dropping to $21.57 per share amidst competitive pressures in the central nervous system (CNS) disorder treatment market. Despite this, analysts largely maintain a "Moderate Buy" rating with an average price target of $31.00, suggesting a potential 43.7% upside. The company remains profitable with a 34.30% net margin, and its decline is attributed more to broader sector volatility than company-specific issues.
Acadia Pharmaceuticals (ACAD) lags Q1 earnings and revenue estimates
Acadia Pharmaceuticals (ACAD) reported its Q1 earnings, missing both analyst estimates for earnings per share and revenue. This financial performance indicates a challenging quarter for the pharmaceutical company against market expectations.
ACADIA Pharmaceuticals Targets $1B Brand Opportunity as Key Neuropsychiatry Data Looms
ACADIA Pharmaceuticals is focusing on expanding its two commercial brands, NUPLAZID and DAYBUE, aiming for a combined $1 billion opportunity by 2028. The company is also preparing for crucial clinical data readouts for remlifanserin in Alzheimer's disease psychosis and Lewy body dementia, and ACP-211 for major depressive disorder. Strategic adjustments include increasing sales forces, direct-to-consumer campaigns, and new formulations to drive growth and address unmet medical needs.
ACADIA Pharmaceuticals Targets $1B Brand Opportunity as Key Neuropsychiatry Data Looms
ACADIA Pharmaceuticals is targeting a $1 billion opportunity for its commercial brands, NUPLAZID and DAYBUE, by 2028 through expanded physician reach and improved patient support. The company is also anticipating key clinical data readouts for its neuropsychiatric pipeline, including phase 2 data for remlifanserin in Alzheimer's disease psychosis later this year, and a proof-of-concept readout for ACP-211 in major depressive disorder next year. These efforts aim to stabilize ACADIA's commercial business and unlock new growth opportunities in CNS disorders.
UBS Group AG Buys 104,546 Shares of ACADIA Pharmaceuticals Inc. $ACAD
UBS Group AG has increased its stake in ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) by 15.7% in the fourth quarter, acquiring an additional 104,546 shares. The investment firm now holds a total of 769,392 shares valued at approximately $20.55 million. Despite ACADIA reporting mixed quarterly results with an EPS miss and revenue slightly below estimates, analysts maintain a "Moderate Buy" rating for the stock with an average price target of $31.00.
A Look At ACADIA Pharmaceuticals (ACAD) Valuation After Mixed Q1 2026 Results And EU Trofinetide Setback
ACADIA Pharmaceuticals (ACAD) reported mixed Q1 2026 results with 10% revenue growth but weaker earnings and a setback for trofinetide in Europe. Despite a strong 33.28% one-year return, the share price has struggled year-to-date, suggesting cooling short-term momentum. The company is considered undervalued by some analysts, with a fair value of $28.75 against a current trading price of $22.57, highlighting potential upside balanced against elevated R&D costs and revenue concentration risks.
ACADIA Pharmaceuticals Inc. Earnings Missed Analyst Estimates: Here's What Analysts Are Forecasting Now
ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) reported first-quarter results that missed analyst expectations, with revenue and statutory earnings per share coming in below forecasts. Following these results, analysts have lowered their EPS estimates for 2026, though revenue expectations remain largely unchanged. Despite the reduced earnings outlook, the consensus price target for ACADIA Pharmaceuticals has held steady, suggesting that analysts do not expect the earnings decline to significantly impact the company's valuation.
Earnings Miss: ACADIA Pharmaceuticals Inc. Missed EPS By 58% And Analysts Are Revising Their Forecasts
ACADIA Pharmaceuticals Inc. reported disappointing first-quarter results, with revenue 4.6% below expectations and statutory earnings per share missing forecasts by 58%. While analysts have significantly cut their EPS forecasts for 2026, the consensus price target remains broadly unchanged, suggesting the market believes the decline will not severely impact valuation. The company's revenue growth is still expected to align with the overall industry's trajectory.
A Look At ACADIA Pharmaceuticals (ACAD) Valuation After Mixed Q1 2026 Results And EU Trofinetide Setback
ACADIA Pharmaceuticals (ACAD) reported mixed Q1 2026 results with 10% revenue growth but weaker earnings and a setback for trofinetide in Europe. Despite these challenges, ACADIA's stock shows a 33.28% one-year return and analysts see the company as undervalued with a fair value of $28.75. The valuation hinges on balancing clinical ambition with financial discipline and disciplined execution in its specialized neurology and rare disease focus.
Acadia Pharmaceuticals (ACAD) Margin Expansion To 34.3% Tests Bearish Growth Concerns
Acadia Pharmaceuticals (ACAD) recorded Q1 2026 revenue of $268.1 million and basic EPS of $0.02, alongside a 34.3% net profit margin and 64.1% earnings growth over the last 12 months. While bulls point to a low P/E ratio and strong profitability, bears highlight slower projected revenue growth compared to the market and quarterly EPS volatility, suggesting a mixed sentiment around the stock's future trajectory. Investors are encouraged to review the full analysis to assess long-term growth, risks, and valuation.
Acadia Pharmaceuticals (ACAD) Margin Expansion To 34.3% Tests Bearish Growth Concerns
Acadia Pharmaceuticals (ACAD) reported Q1 2026 revenue of $268.1 million and basic EPS of $0.02, alongside a trailing twelve-month net profit margin of 34.3% and 64.1% earnings growth. While bulls point to a low P/E ratio and strong profitability, bears highlight slower forecast revenue growth compared to the market, and quarterly EPS volatility, suggesting mixed sentiment regarding the sustainability of its growth.
ACADIA Pharmaceuticals stock (US0042251084): Focus on CNS drug pipeline and commercial execution
ACADIA Pharmaceuticals is highlighted for its work in advancing its central nervous system (CNS) drug pipeline and commercial execution of its marketed products, particularly Nuplazid. The company's strategy involves developing treatments for complex CNS conditions with unmet medical needs. For US investors, ACADIA offers exposure to the CNS therapeutics segment, a high-risk, high-reward area of the healthcare market.
Acadia Pharmaceuticals Reports First Quarter 2026 Financial Results and Reaffirms 2026 Financial Guidance
Acadia Pharmaceuticals announced strong financial results for the first quarter of 2026, with total revenues reaching $268 million, a 10% increase year-over-year. This growth was primarily driven by DAYBUE net sales of $101 million and NUPLAZID net sales of $167 million. The company has reaffirmed its full-year 2026 financial guidance, anticipating total revenues between $1.22 and $1.28 billion, and is progressing with its pipeline, including the expected Phase 2 topline data for remlifanserin in Alzheimer’s disease psychosis later this year.
ACADIA Pharmaceuticals Q1 2026 Earnings Call Highlights – DAYBUE and NUPLAZID Update - News and Statistics
ACADIA Pharmaceuticals held its Q1 2026 earnings call on May 6, 2026, with CEO Catherine Owen Adams, CCO Thomas Garner discussing DAYBUE and NUPLAZID, and EVP Elizabeth Thompson providing pipeline updates, while CFO Mark C. Schneyer reviewed financials. The company discussed both GAAP and non-GAAP financial measures, including non-GAAP NUPLAZID net sales and total revenues. The call also included forward-looking statements subject to various risks and uncertainties.
Is ACADIA Pharmaceuticals (ACAD) Offering Value After A 45% One Year Share Price Gain?
ACADIA Pharmaceuticals has seen a 45% gain over the last year, despite a recent 18.3% year-to-date drop. Two valuation approaches, Discounted Cash Flow (DCF) and Price-to-Earnings (P/E) ratio, suggest the stock is undervalued, with the DCF model indicating a 77.9% intrinsic discount. The article also presents "bull" and "bear" narratives for the company, highlighting potential opportunities in specialized care and risks associated with product reliance and pricing pressure.
ACAD Q1 Earnings & Revenues Miss Estimates Despite Y/Y Sales Growth
Acadia Pharmaceuticals (ACAD) reported Q1 2026 earnings and revenues that missed analyst estimates, despite a 10% year-over-year sales increase driven by its products Nuplazid and Daybue. The company reaffirmed its 2026 financial outlook but faced a regulatory setback in the EU for trofinetide. ACAD also provided updates on its pipeline, including the ongoing rollout of Daybue Stix and anticipated data from its phase II RADIANT study.
Earnings call transcript: ACADIA Pharmaceuticals misses Q1 2026 EPS forecast
ACADIA Pharmaceuticals reported a significant earnings and revenue miss for Q1 2026, with an EPS of $0.02 against a forecast of $0.05 and revenue of $268 million versus $280.92 million. Despite this, the stock saw a 1.25% increase in aftermarket trading. The company maintained its full-year 2026 revenue guidance, projecting stronger contributions in the second half of the year, driven by commercial growth and upcoming pipeline catalysts like the remlifanserin Phase II readout.
Acadia (NASDAQ: ACAD) reaffirms 2026 outlook after Q1 results
Acadia Pharmaceuticals (NASDAQ: ACAD) reported Q1 2026 total revenues of $268 million, a 10% increase year-over-year, driven by strong sales of NUPLAZID and DAYBUE. Despite an increase in operating expenses leading to a lower net income of $3.6 million, the company reaffirmed its full-year 2026 financial guidance. Acadia also highlighted upcoming Phase 2 topline results for remlifanserin in Alzheimer’s disease psychosis, expected between August and October 2026.
ACADIA PHARMACEUTICALS ($ACAD) Releases Q1 2026 Earnings
ACADIA PHARMACEUTICALS ($ACAD) reported Q1 2026 earnings, missing analyst estimates for both earnings per share and revenue. The company's stock price saw a decline of -4.47% since market close. Insider trading data reveals significant selling activity by company executives, while institutional investors show mixed movements in their holdings.
Acadia Pharmaceuticals Reports First Quarter 2026 Financial Results and Reaffirms 2026 Financial Guidance
Acadia Pharmaceuticals reported robust first-quarter 2026 financial results, with total revenues reaching $268 million, a 10% increase year-over-year. The company reaffirmed its full-year 2026 financial guidance, anticipating total revenues between $1.22 and $1.28 billion. Key drivers included strong sales of DAYBUE ($101 million) and NUPLAZID ($167 million), and the company is on track to release Phase 2 topline data for remlifanserin in Alzheimer’s disease psychosis between August and October 2026.
ACADIA Pharmaceuticals earnings up next: Can drug sales sustain momentum?
ACADIA Pharmaceuticals is set to report its first-quarter results, with analysts expecting earnings of 5 cents per share on revenue of $280.9 million. Investors will be closely watching for updates on Nuplazid and Daybue sales performance, following recent investments and regulatory setbacks, as well as progress on the remlifanserin pipeline, which could be a significant future catalyst.
Acadia: Q1 Earnings Snapshot
Acadia Pharmaceuticals Inc. reported first-quarter earnings of $3.6 million, or 2 cents per share, falling short of analyst expectations of 4 cents per share. The company's revenue of $268.1 million also missed Street forecasts of $282.2 million. Despite the miss, Acadia projects full-year revenue between $1.22 billion and $1.28 billion, and its shares have seen a 49% rise in the last 12 months.
R&D Leadership Transition and Trial Continuity Could Be A Game Changer For ACADIA Pharmaceuticals (ACAD)
ACADIA Pharmaceuticals is undergoing an R&D leadership transition as Dr. Elizabeth H.Z. Thompson retires but remains as a consultant to ensure continuity for key remlifanserin trials
Acadia: Q1 Earnings Snapshot
Acadia Pharmaceuticals Inc. (ACAD) reported first-quarter earnings of $3.6 million, or 2 cents per share, missing analyst expectations of 4 cents per share. Revenue for the period was $268.1 million, also falling short of the $282.2 million forecasted by analysts. Despite a 49% rise in shares over the last 12 months, Acadia shares have decreased 19% since the beginning of the year.
Acadia Pharmaceuticals (ACAD) CFO sells shares to cover RSU taxes
Acadia Pharmaceuticals' EVP and CFO, Mark C. Schneyer, sold 3,506 shares of common stock at a weighted average price of $21.79 per share to cover withholding taxes related to the vesting of 6,815 restricted stock units. This transaction, executed on May 4, 2026, was consistent with Rule 10b5-1(c) requirements. After the sale, Schneyer directly holds 66,145 shares of the company.
Acadia Pharmaceuticals CFO Mark Schneyer sells $76,395 in stock
Acadia Pharmaceuticals CFO Mark Schneyer sold 3,506 shares worth $76,395 to cover tax obligations related to the vesting of restricted stock units. This transaction, executed under a Rule 10b5-1 plan, occurred after 6,815 restricted stock units vested on May 1, 2026. The article also mentions recent company news, including a negative opinion from the European Medicines Agency on trofinetide and a fluctuating analyst rating from BofA Securities.
R&D Leadership Transition and Trial Continuity Could Be A Game Changer For ACADIA Pharmaceuticals (ACAD)
ACADIA Pharmaceuticals is navigating a leadership transition in its R&D department, with the Head of R&D retiring but remaining as a consultant to ensure continuity for key remlifanserin trials. This planned transition aims to maintain stability as the company's late-stage pipeline, particularly remlifanserin for Alzheimer's and Lewy Body Dementia psychosis, progresses. The company's investment narrative is closely tied to its neurology and rare disease portfolio and the successful execution of trials, with remlifanserin's Phase 2 data being a crucial near-term catalyst.
FDA Approval for NUPLAZID issued to ACADIA PHARMS INC
Quantisnow reports an FDA approval for NUPLAZID, issued to ACADIA PHARMS INC (ACAD). The report, delivered via Quantisnow's real-time market data platform, highlights the significance of this regulatory milestone for the healthcare company. Quantisnow aggregates various market data points for retail investors, including SEC filings, FDA approvals, and analyst ratings.
ACADIA Pharmaceuticals (ACAD) Q1 2026 Preview: EPS Est. $0.08, Reports May 6
ACADIA Pharmaceuticals (ACAD) is expected to report Q1 2026 results on May 6th, with an anticipated EPS of $0.08 and revenue of $280.3M. Analyst confidence has significantly declined, with the EPS consensus falling 38.5% over the past 90 days. Despite projected revenue growth of 14.7% year-over-year, EPS is forecast to drop 27.3%, largely due to concerns over operating expenses and R&D investments.
ACADIA Pharmaceuticals (ACAD) Q1 2026 Preview: EPS Est. $0.08, Reports May 6
ACADIA Pharmaceuticals (ACAD) is expected to report Q1 2026 earnings on May 6, with Wall Street analysts forecasting an EPS of $0.08 on revenue of $280.3 million. Despite a projected 14.7% year-over-year revenue growth, EPS is expected to decline by 27.3% from the year-ago quarter, signaling potential concerns about operating expenses or product mix. Analysts have lowered their EPS estimates by 11.1% over the past 30 days and 38.5% over the past 90 days, indicating increasing caution.
Acadia R&D Chief Plans Retirement As Company Stresses Pipeline Continuity
ACADIA Pharmaceuticals (NasdaqGS:ACAD) announced the retirement of its Head of Research and Development, Dr. Elizabeth H.Z. Thompson, who will remain as a consultant through 2026 to ensure continuity for key clinical readouts. This transition is critical for investors, as R&D leadership shapes priorities and capital allocation, especially for drug developers focusing on central nervous system conditions. The company aims to mitigate concerns about disrupted clinical decision-making by retaining Dr. Thompson and seeking an experienced successor.
ACADIA (ACAD) Upgraded to Buy After Recent Pullback
BofA Securities upgraded ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD) to Buy from Neutral, maintaining a $29 price target. The upgrade follows a nearly 25% share price drop attributed to macroeconomic factors rather than company fundamentals. BofA highlighted consistent Nuplazid sales, potential for $888 million in peak sales, and an $11 billion pipeline opportunity as reasons for optimism.
ACADIA Pharmaceuticals | 8-K: Current report
This document is an 8-K current report filed by ACADIA Pharmaceuticals. An 8-K report is used by public companies to announce major events that shareholders should know about.
A Look At ACADIA Pharmaceuticals (ACAD) Valuation As Recent Returns Send Mixed Signals
ACADIA Pharmaceuticals (ACAD) is currently undervalued according to investor narratives, trading at US$21.95 against a fair value of $28.75. Despite mixed short-term returns, the company shows long-term resilience, focusing on specialized neurological and psychiatric conditions. This valuation suggests a potential opportunity for investors, though the narrative acknowledges risks related to clinical trials and commercial reach.
Acadia Pharmaceuticals (ACAD) Tops Q1 Earnings and Revenue Estimates (Revised)
Acadia Pharmaceuticals (ACAD) exceeded both earnings and revenue estimates for the first quarter. The company reported adjusted earnings of $0.09 per share, significantly beating the Zacks Consensus Estimate, and generated revenues of $150.36 million, also surpassing expectations. This positive financial performance indicates a strong start to the year for Acadia.
Acadia Pharmaceuticals Announces Planned Year-End Retirement of Elizabeth H.Z. Thompson, Ph.D., Head of Research and Development, Following a Distinguished Career
Acadia Pharmaceuticals (Nasdaq: ACAD) announced the planned year-end retirement of Elizabeth H.Z. Thompson, Ph.D., Head of Research and Development, for personal reasons. Dr. Thompson will continue in her role until a successor is appointed and will serve as a consultant through at least the end of 2026 to ensure continuity during key clinical study readouts. The company has initiated a search for a new R&D leader and confirmed that all ongoing clinical trials, including those for remlifanserin in Alzheimer’s disease psychosis and Lewy Body Dementia Psychosis, are advancing as planned.
FDA Approval for NUPLAZID issued to ACADIA PHARMS INC
The article reports that the FDA has issued approval for NUPLAZID to ACADIA PHARMS INC. This information was delivered by Quantisnow, a real-time market data and news platform for retail investors that aggregates various financial data points. The article also provides recent analyst ratings and related press releases concerning Acadia Pharmaceuticals.
Acadia Pharmaceuticals (NASDAQ: ACAD) details R&D head’s planned retirement and transition
Acadia Pharmaceuticals announced the planned retirement of Elizabeth H.Z. Thompson, Ph.D., its Head of Research and Development, for personal reasons. Dr. Thompson will remain in her role during a transitional period and then serve as a consultant through at least the end of 2026 to ensure continuity, particularly for the remlifanserin clinical studies. The company has initiated a search for a new R&D head while confirming that all ongoing clinical trials are proceeding as planned.
Pictet Asset Management Holding SA Buys 84,055 Shares of ACADIA Pharmaceuticals Inc. $ACAD
Pictet Asset Management Holding SA has increased its stake in ACADIA Pharmaceuticals Inc. by 5.7%, now owning 1,547,103 shares valued at approximately $41.5 million. This increase follows ACADIA's strong financial performance, including an EPS of $1.60 and revenue of $298 million, significantly exceeding analyst expectations. Wall Street analysts maintain a positive outlook, with an average "Moderate Buy" rating and a price target of $31.21.
ACADIA Pharmaceuticals (ACAD) to Release Earnings on Wednesday
ACADIA Pharmaceuticals is scheduled to release its Q1 2026 earnings on Wednesday, May 6th, with analysts forecasting $0.06 EPS and $281.80 million in revenue. The company previously surprised with $1.60 EPS against a $0.12 consensus in Q4 2025, and analysts currently hold a "Moderate Buy" consensus rating with an average price target of $31.21. Insider transactions show executive-level selling, with approximately 10,689 shares sold in the last quarter.
FDA Approval for NUPLAZID issued to ACADIA PHARMS INC
The FDA has approved NUPLAZID, issued to ACADIA PHARMS INC. This news was delivered by Quantisnow, a real-time market data and news platform for retail investors. The article highlights recent analyst ratings for ACADIA Pharmaceuticals Inc. and lists related regulatory and company news.
FDA Approval for NUPLAZID issued to ACADIA PHARMS INC
ACADIA Pharmaceuticals Inc. (ACAD) has received FDA approval for its drug NUPLAZID. This approval was reported by Quantisnow, a real-time market data platform that aggregates various financial information for retail investors. The article also provides recent analyst ratings for ACADIA Pharmaceuticals.
Vanguard files Schedule 13G: ACAD (NASDAQ: ACAD) 8.78M shares, 5.15%
Vanguard Portfolio Management has filed a Schedule 13G, disclosing beneficial ownership of 8,781,007 shares of ACADIA Pharmaceuticals Inc. common stock, which represents 5.15% of the class. The filing indicates that Vanguard has sole dispositive power over all these shares but limited sole voting power to 109,362 shares. This disclosure, as of March 31, 2026, does not suggest any intent to influence the company's governance.
Here's why Acadia Pharmaceuticals (ACAD) is a strong momentum stock
This article from MSN discusses why Acadia Pharmaceuticals (ACAD) is considered a strong momentum stock. It suggests that the company exhibits characteristics indicating upward price movement. The content likely delves into factors contributing to this assessment.
